Prometheus inks US commercialisation deal with Wilex for renal cancer drug
This article was originally published in Scrip
Executive Summary
In what Wilex CEO Olaf Wilhelm called the "deal we have been looking for," the German drug maker granted US commercialisation rights for Rencarex (girentuximab), a Phase III product candidate for adjuvant use in non-metastatic clear-cell renal cell cancer (ccRCC) – the most prevalent form of kidney cancer – to US specialty pharma and diagnostics firm Prometheus Laboratories.